Survival benefits were revealed for patients with metastatic gastrointestinal stromal tumors (GISTs) who underwent both locoregional treatment (LRT) and surgery, as published in Cancers.
The researchers retrospectively reviewed a cohort of 127 patients with either recurrent or de novo metastatic GIST in British Columbia between January 2008 and December 2017.
“This study is among the first to systematically examine the use of various LRT in metastatic GIST management,” the authors wrote. “Integration of LRT with systemic treatments may potentially provide a promising durable response and prolonged survival for highly selected metastatic GIST patients with low volume disease, limited progression and otherwise well controlled on systemic treatments.”
Read more about GIST treatment
The research team systematically assessed the clinical outcomes of patients with metastatic GISTs undergoing radical resection of the primary tumor or metastasectomy as well as ablation therapies including radiofrequency ablation and microwave ablation.
Although surgery is well established in the treatment of metastatic sarcoma, it is not currently considered standard care for patients with metastatic GISTs, mainly due to a lack of evidence from large prospective randomized controlled trials. However, there are prospective studies that suggest good outcomes for select patients with metastatic GISTs, including long-term survival and longer time to disease progression than patients who do not undergo surgery or LRT.
The research team found the best survival results among the subset of patients with a slow or low volume of progressive metastatic GIST who were well controlled by systemic approaches. For further clarity on patient selection and LRT options, the authors note that future studies are planned that will combine data from various institutions with the aim of optimizing clinical outcomes for patients with metastatic GISTs.
Patterson T, Li H, Chai J, et al. Locoregional treatments for metastatic gastrointestinal stromal tumor in British Columbia: a retrospective cohort study from January 2008 to December 2017. Cancers. 2022;14(6):1477. doi.10.3390/cancers14061477